Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price traded down 4% during trading on Wednesday . The stock traded as low as $2.86 and last traded at $2.90, with a volume of 193,287 shares changing hands. The stock had previously closed at $3.02.

Several equities analysts have commented on the company. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 9th. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. HC Wainwright initiated coverage on Anthera Pharmaceuticals in a research report on Friday, July 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Anthera Pharmaceuticals has an average rating of “Buy” and an average price target of $9.58.

The stock’s market cap is $121.59 million. The stock has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.42.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. On average, analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.37) earnings per share for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.